background

CARIM employs 250 researchers from 13 disciplines, about 100 PhD students and 50 technical and support staff members. Together, they are unraveling the mechanisms of cardiovascular diseases.

With an annual budget of approximately 20,500,000 Euros, CARIM is one of the largest cardiovascular research institutes in Europe, producing more than 500 scientific articles and approximately 30 PhD dissertations per year.

In the last ten years CARIM papers were published in high impact journals such as New England Journal of Medicine, JAMA, Nature Medicine, Journal of Experimental Medicine, Circulation, Lancet Neurology, and Journal of American College of Cardiology. Bibliometric analyses (1997-2009) illustrate that publications from CARIM have been cited 1.61 times more often than the world mean for the cardiovascular field.

CARIM is one of the five schools of the Faculty of Health, Medicine and Life Sciences (FHML) of Maastricht University and is embedded within the Maastricht University Medical Center+ (Maastricht UMC+).
Download here the brochure of Maastricht University Medical Center+.

1. a very broad range of facilities covering the entire field of translational cardiovascular research and many internship opportunities, taking advantage of its connection with a large academic hospital;
2. an open and dynamic work culture in which talented and ambitious young people work side by side with renowned researchers; 
3. an active organisation that nurtures its employees, providing support, such as assistance with applications for research grants and funding,  a talent development program and a Research Council (which reviews all project proposals before they are submitted).

Thus CARIM provides a dynamic, critical learning environment, which proves to be fertile ground for top achievements in the field of cardiovascular research.

• Annual budget: K
• Researchers: 196 fte
• Technical and supporting staff: 77 fte
• Departments/disciplines: 13
• Scientific articles: 585 (Wi-1: 520)
• PhD Thesis: 50
• Patents: 4

CARIM is one of the initiators of the Maastricht Study; a large, longitudinal population based cohort study focused on type 2 diabetes, and its related co-morbidities. The study will include and track 10.000 individuals living in the Southern part of the Netherlands over a ten-year period. Participants are 40 to 75 years old, and half of them will have type 2 diabetes. For more detailed information please see: www.demaastrichtstudie.nl.

CARIM plays an important role in public-private research partnerships as main author and project manager of 6 out of 7 cardiovascular projects of the Center for Translational Molecular Medicine (CTMM) in the Netherlands. CTMM is a public-private consortium that comprises universities, academic medical centres, medical technology enterprises and chemical and pharmaceutical companies.

Other public-private research partnerships in which our researchers participate are: the BioMedical Materials program (BMM) and Top Institute Pharma. In addition, CARIM is a member of several international networks, including the EU seventh Framework Programme (FP7) and the Leducq Transatlantic Network. CARIM is part of Maastricht University.